Abstract
The culture of freshly isolated lymphocytes for three to five days in vitro with a lymphokine preparation rich in interleukin 2 (IL-2), results in the generation of effector cells capable of lysing a variety of tumour cells1. This phenomenon has been described as lymphokine activated killing (LAK) and represents a lytic system distinct from that of natural killer (NK) cells2 and cytotoxic T lymphocytes3. Subsequent studies have revealed that LAK cells mainly arise from non-B, non-T lymphoid cell precursors and are capable of expanding for short times both in vivo and in vitro when stimulated by IL-24.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lotze M.T., Grimm EA., Mazumder A., Strausser J.L., Rosenberg S.A., Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T cell growth factor. Cancer Res. 41: 4420, (1981).
Grimm EA., Maxumder A., Zhang H.Z., Rosenberg S.A., Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interkeukin 2 activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155: 1823, (1982).
Grimm EA., Ramsey K.M. Mazumder A., Wilson DJ., Djeu J.Y., Rosenberg S.A., Lymphokine activated killer cell phenomenon II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes and natural killer cells. J. Exp. Med. 157: 884, (1983).
Ettinghausen S.E., Lipford E.H., Mule J.J., Rosenberg S.A., Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer cells. J. Immunol. 135: 3623, (1985).
Ettinghausen S.E., Rosenberg S.A., Immunotherapy of murine sarcomas using lymphokine activated killer cells: Optimization of the schedule and route of administration of recombinant interleukin 2. Cancer Res. 46: 2784, (1986).
Jacobs S.K., Wilson DJ., Kornblith P.L., Grimm EA., Interleukin 2 and autologous lymphokine activated killer cells in the treatment of malignant glioma. J. Neurosurg. 64: 743, (1986).
Zarling J.M., Eskra L., Borden E.C., Horoszewicz J., Carter W.A., Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J. Immunol. 123: 63, (1979).
Yates J., Glidewell O., Wiernik P., Cooper M.R., Steinberg D., Dosik H., Levy R., Hoagland C., Henry P., Gottlieb A., Cornell C, Berenberg J., Hutchinson J.L., Raich P., Nissen N., Ellison R.R., Frelick R., James G.W., Falkson G., Silver R.T, Haurani F., Green M., Henderson E., Leone L., Holland J.F., Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454, (1982).
Andersson C.C., Nilsson K., Gahmberg C.G., K562-a human erythroleukaemic cell Une. Int. J. Cancer 23: 143, (1979).
Sundstron C, Nilsson K., Establishment and characterization of a human histiocytic lymphoma cell line (U937). Int. J. Cancer 17: 565, (1976).
Brunner K., Engers H., Cerottini J.C., The Cr release assay as used for the quantitative measurement of cell-mediated cytolysis in vitro, in: “In vitro methods in cell mediated and tumor immunity,” Bloom B, David J eds., Academic Press 1976, p 423.
Mazumder A., Rosenberg S.A., Successful immunotherapy of natural killer-resistant established pulmonary metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med. 159: 495, (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Plenum Press, New York
About this chapter
Cite this chapter
Tratkiewicz, J.A., Szer, J., Boyd, R.L. (1988). Are Lymphokine Activated Killer Cells a Possible Form of Leukaemia Immunotherapy?. In: Fossum, S., Rolstad, B. (eds) Histophysiology of the Immune System. Advances in Experimental Medicine and Biology, vol 237. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-5535-9_68
Download citation
DOI: https://doi.org/10.1007/978-1-4684-5535-9_68
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-5537-3
Online ISBN: 978-1-4684-5535-9
eBook Packages: Springer Book Archive